CN114343184A - Preparation method of ammonia sugar composite functional tablet - Google Patents
Preparation method of ammonia sugar composite functional tablet Download PDFInfo
- Publication number
- CN114343184A CN114343184A CN202210151242.5A CN202210151242A CN114343184A CN 114343184 A CN114343184 A CN 114343184A CN 202210151242 A CN202210151242 A CN 202210151242A CN 114343184 A CN114343184 A CN 114343184A
- Authority
- CN
- China
- Prior art keywords
- extract
- mixture
- mixing
- tablets
- glucosamine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000002131 composite material Substances 0.000 title claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 title description 4
- 229910021529 ammonia Inorganic materials 0.000 title description 2
- 239000003826 tablet Substances 0.000 claims abstract description 40
- 238000002156 mixing Methods 0.000 claims abstract description 34
- 229940075000 frankincense extract Drugs 0.000 claims abstract description 33
- 239000002245 particle Substances 0.000 claims abstract description 28
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 22
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 21
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 21
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 14
- 235000020721 horse chestnut extract Nutrition 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 12
- 235000020744 piper nigrum extract Nutrition 0.000 claims abstract description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 7
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229960000913 crospovidone Drugs 0.000 claims abstract description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 6
- 238000003825 pressing Methods 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000007891 compressed tablet Substances 0.000 claims abstract description 4
- 229940057948 magnesium stearate Drugs 0.000 claims abstract description 4
- 229960001866 silicon dioxide Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 42
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 29
- 235000020240 turmeric extract Nutrition 0.000 claims description 22
- 239000008513 turmeric extract Substances 0.000 claims description 22
- 229940052016 turmeric extract Drugs 0.000 claims description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 20
- 239000002002 slurry Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 13
- 244000163122 Curcuma domestica Species 0.000 claims description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 210000004911 serous fluid Anatomy 0.000 claims description 9
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 229920003082 Povidone K 90 Polymers 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 33
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 244000164480 Curcuma aromatica Species 0.000 abstract 3
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 description 22
- 230000004054 inflammatory process Effects 0.000 description 21
- 241000252212 Danio rerio Species 0.000 description 20
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 19
- 229960002442 glucosamine Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 description 8
- 229940059329 chondroitin sulfate Drugs 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 6
- 229960002849 glucosamine sulfate Drugs 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 206010057178 Osteoarthropathies Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000001179 synovial fluid Anatomy 0.000 description 5
- 235000018062 Boswellia Nutrition 0.000 description 4
- 240000007551 Boswellia serrata Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229910000365 copper sulfate Inorganic materials 0.000 description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000055008 Matrilin Proteins Human genes 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 3
- 229940075559 piperine Drugs 0.000 description 3
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 3
- 235000019100 piperine Nutrition 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000157282 Aesculus Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010181 horse chestnut Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000004267 spermatic cord Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940110210 glucosamine chewable tablet Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008250 pharmaceutical cream Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of glucosamine hydrochloride curcuma extract tablets, which comprises the steps of preparing glucosamine hydrochloride curcuma extract particles, preparing frankincense extract particles, fully mixing the glucosamine hydrochloride curcuma extract particles and the frankincense extract particles with sodium chondroitin sulfate, horse chestnut extract, black pepper extract, vitamin C, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, crospovidone and magnesium stearate, and pressing into tablets; and finally coating the compressed tablets to obtain the tablets. The invention adopts Chinese and western medicines to form a compound, selects the components and the contents, and utilizes the direct synergistic effect of the components to enhance the bioavailability and greatly enhance the anti-inflammatory and disinfection effects.
Description
Technical Field
The present invention is a divisional application of the invention application (202011599893.8). The invention belongs to the technical field of food, and particularly relates to a preparation method of an ammonia-sugar composite functional tablet.
Background
The osteoarthropathy is used as a refractory disease and breaks down countless patients, and the osteoarthropathy is prevented and treated inevitably. Glucosamine and chondroitin sulfate are used as dietary supplements with wide sources, and have the effects of preventing and treating osteoarthropathy of middle-aged and elderly people and some special people. Glucosamine can reduce the concentration of proinflammatory transcription factors, enhance the toughness of specific parts of cartilage, and prevent collagen denaturation by inhibiting the activity of hydrolytic enzymes and reducing lipid and protein oxidation. Glucosamine can improve the metabolic function and nutrient absorption of bone and cartilage tissues by stimulating the biochemical synthesis of mucopolysaccharide and increasing the uptake of bone calcium, can also improve and enhance the viscosity of synovial fluid, is also a basic substance for proteoglycan synthesis, can specifically act on articular cartilage, recover the normal metabolic function of chondrocytes, stimulate the production of proteoglycans with normal polymer structures by chondrocytes, and can also inhibit the activity of enzymes which damage cartilage, such as collagenase and phospholipase A2.
Chondroitin sulfate functions by inhibiting the activity of the mitogen-activated protein kinase p38MAPK and the signal-regulated kinase ERK1/2, reducing nuclear translocation of nuclear transcription factor kappa B (NF-kappa B), reducing the synthesis of proteolytic enzymes (matrix metalloproteinases-3, MMP-3), MMP-9, MMP-13, cathepsin B, etc.), inflammation-inducing enzymes (phospholipase a2, cyclooxygenase-2, nitric oxide synthase-2), and proinflammatory cytokines (interleukin-1 β). The combination of glucosamine and chondroitin sulfate can promote the synthesis of type II collagen in human articular chondrocytes, reduce the death of the chondrocytes and keep the balance of anabolism and catabolism of cartilage extracellular matrix. Glucosamine and chondroitin sulfate protect articular chondrocytes through the above-mentioned series of action mechanisms.
The prevention of osteoarthropathy is important in daily life, and if glucosamine and chondroitin sulfate can be matched to prepare food by the time of three meals a day and the medium of food, the aims of strengthening bones and preventing osteoarthropathy can be achieved.
Glucosamine as a drug has many disadvantages such as high hygroscopicity, high susceptibility to oxidative discoloration of the amino group, and high requirement for the formulation of glucosamine, such as the need for coating of tablets, filling of ampoules, sealing of capsule shells with capsules, and the need for moisture and oxygen resistance. In addition, most commercially available glucosamine products have low content of effective drugs, poor stability and low bioavailability, and the products aiming at osteoarthritis or bone injury or osteoporosis in the current domestic and foreign markets have various types and uneven quality, and the existing dietary supplements in the market have the problems of single nutrient component, unreasonable composition and matching proportion or unreasonable dosage and the like, so that various functional components cannot be well absorbed and utilized in the human body, and the ideal repairing and treating effects cannot be achieved.
Therefore, the development and research of novel glucosamine chondroitin sulfate products for replacing the existing glucosamine and chondroitin sulfate medicines have great significance for strengthening bones and preventing osteoarticular diseases.
Disclosure of Invention
The invention aims to provide a preparation method of an ammonia-sugar composite functional tablet, which has better effects on the aspects of inflammation diminishing and bacteria resistance.
In order to achieve the above object, the present invention provides a method for preparing the glucosamine complex functional tablet, comprising the following steps: s1, mixing D-glucosamine hydrochloride, the turmeric extract and povidone K30 to form a mixture A, mixing povidone K90 with water to prepare 5% serous fluid, mixing the mixture A into the serous fluid, fully dissolving the mixture A until the mixture A is clear and transparent, putting the obtained mixed material into a wet granulator, and uniformly stirring the mixture A and the serous fluid to obtain glucosamine hydrochloride turmeric extract particles; s2, mixing the frankincense extract, calcium carbonate and hydroxypropyl methylcellulose to obtain a mixture B, preparing 1% slurry by using a proper amount of water and the hydroxypropyl methylcellulose, mixing the mixture B into the slurry, fully dissolving the mixture B until the mixture B is clear and transparent, putting the obtained mixed material into a wet granulator, uniformly stirring, and granulating by a wet method to obtain frankincense extract particles; s3, mixing the glucosamine hydrochloride curcuma extract particles and the frankincense extract particles with sodium chondroitin sulfate, horse chestnut extract, black pepper extract, vitamin C, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, crospovidone and magnesium stearate, and pressing into tablets; s4, preparing a coating premix into a solution with the concentration of 20%, and coating the compressed tablets obtained in the step S3 to obtain the tablets.
According to the present invention, in the step S1, D-glucosamine hydrochloride of 77.6 wt%, turmeric extract of 20 wt%, and povidone K30 of 2 wt% are mixed, and povidone K90 of 0.4 wt% is mixed with water to prepare a syrup of 5% concentration; in the step S2, the frankincense extract 52 wt%, calcium carbonate 47 wt%, and hypromellose 1 wt% are mixed, and a slurry with a concentration of 1% is prepared by mixing appropriate amount of water with hypromellose.
The invention has the beneficial effects that:
1) the compound is prepared from glucosamine hydrochloride, sodium chondroitin sulfate, frankincense extract, black pepper extract, horse chestnut extract, turmeric extract, vitamin C and other Chinese and western medicine raw materials, the mixture ratio of the raw material components in the compound is subjected to compatibility and selection, and the synergistic effect of the components is utilized, so that the bioavailability is greatly improved, and the product has better functions in the aspects of inflammation diminishing and bacteria resisting. The curcumin in the curcuma extract and the piperine in the black pepper extract play a vital auxiliary role in relieving inflammation, the effects of the frankincense extract and the horse chestnut extract are utilized, the glucosamine content in the tablet is increased, the nutrition and health care functions are increased, the tablet can be directly chewed for use, the absorption of a human body is not influenced, the dissolution is rapid, the tablet is suitable for patients with dysphagia, and the stability is good.
2) In view of the defect that the frankincense extract is easy to absorb moisture and strong in cohesiveness of the material, the frankincense extract can generate sticking phenomenon when being directly used for tabletting, and the moisture absorption is easy to generate spots on the surface of the tablet along with the time extension, the invention innovates the preparation process of the frankincense extract particles, greatly improves the material characteristics after the frankincense extract is granulated, avoids the sticking phenomenon, delays the generation of the spots in the product placing process, and lays a good foundation for the industrialization of the product.
3) Because the turmeric extract has large dosage and high proportion in the formula, the powder is fine, the materials are fluffy, the sticking phenomenon can occur during tabletting, and the tablet weight is easy to be unstable.
4) The turmeric extract and the active ingredients in the frankincense extract, the horse chestnut extract and the black pepper extract have synergistic effect, and the curative effect of treating osteoarticular diseases is better than glucosamine therapy which uses glucosamine alone, is also better than the therapy which combines the glucosamine and other components, and is better than the mixed therapy which uses glucosamine and chondroitin sulfate. The active ingredients in the prescription can quickly and directly enter the blood circulation of the bone joint part in high quantity and directly enter the bone joint part of a patient, the effect is fast, the raw materials are all natural, the affinity with the human body is high, no substances such as stimulation, anesthesia and hormone are contained, the treatment effect is obvious, and the long-acting effect is realized without rebound.
Drawings
FIG. 1 is a graph comparing the effect (neutrophil count) of the inflammation of zebrafish between each experimental group and model control group of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail with reference to the accompanying drawings and embodiments. It should be emphasized that the specific embodiments described herein are merely illustrative of the invention, are some, not all, and therefore do not limit the invention. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
The invention adopts silicon dioxide as a lubricant and a glidant, has good compressibility, moderate hardness, good mouthfeel, smooth and tidy appearance, uses microcrystalline cellulose and povidone as a binder, uses croscarmellose sodium as a disintegrant, and adds frankincense extract, horse chestnut extract and black pepper extract, thereby not only ensuring that the obtained glucosamine chewable tablet has high active ingredient and rapid dissolution, but also improving the stability and being difficult to deteriorate.
Chondroitin sulfate is a subfamily of glycosaminoglycan, exists in animal cartilage in a large amount, is acidic mucopolysaccharide extracted from animal cartilage, can promote cartilage regeneration, repair and reverse damage, increase joint synovial fluid volume, effectively relieve joint pain and improve joint function. Cartilage is free of blood supply, and its oxygen supply, nutrients and lubrication are from synovial fluid, chondroitin transports oxygen and nutrients to the cartilage and discharges carbon dioxide and waste products. Matrix metalloproteases and proinflammatory cytokines (e.g., interleukin-1) secreted by joint synoviocytes and chondrocytes are important mediators of cartilage destruction, and abnormal expression thereof has an early warning effect on the development of Osteoarthritis (OA). Chondroitin can reduce damage to cartilage matrix and synovial fluid components by inhibiting the activity of degrading enzymes such as protease; by reducing fibrin thrombosis, improving blood circulation in the synovial membrane of joints and subchondral bone; can be used for preventing and treating arthritis by inhibiting cyclooxygenase-2 activity. The constituent glycosaminoglycans need to be highly sulfated, and the supplementation of the chondroitin sulfate moiety can counteract the adverse effects caused by the reduction of the sulfate component in vivo.
Glucosamine is a natural amino monosaccharide, is a main component for synthesizing proteoglycan in a cartilage matrix, can stimulate the growth of chondrocytes and the synthesis of the cartilage matrix, improve the cartilage metabolism, improve the repair capacity of damaged cartilage, relieve the symptoms of OA pain and improve the joint function. The composition has antiinflammatory, analgesic, and disease development delaying effects. The glucosamine hydrochloride has low price and good curative effect, can promote the synthesis of mucopolysaccharide of a human body, improve the viscosity of joint synovial fluid, improve the metabolism of articular cartilage, can effectively relieve the symptoms of KOA at early and middle stages, has stable long-term curative effect and better long-term administration effect.
The frankincense extract contains 60-70% of resin, 27-35% of gum and 3-8% of volatile oil. Can promote blood circulation to relieve pain, and treat pain due to blood stasis, rheumatism, arthralgia, and traumatic blood stasis and swelling. It also has repercussive and granulation promoting effects, and can be used for treating early stage pyocutaneous disease, red swelling and pain.
Horse chestnut extract is commonly used in pharmaceutical cream or cosmetics in the prior art, and the extract is used as a main functional component of the cream in the medicine and has the function of surface activity and moisture retention. The cosmetic can be used as a colloid material to increase the smoothness and softness of skin and delay the aging of skin. The horse chestnut extract is adopted as a key component, and the horse chestnut extract and other main components have synergistic effect, so that the horse chestnut extract is favorable for resisting tissue edema, reducing vascular permeability, preventing water accumulation in tissues and quickly eliminating heavy feeling and pressure caused by local edema, has obvious effects on resisting inflammation, resisting exudation and relieving swelling, can restore normal permeability of capillary vessels and increase venous tension. In addition, the horse chestnut also has the functions of inhibiting collagenase, hyaluronidase, B-glucuronidase and elastase, and can play roles in promoting blood circulation, promoting wound healing, resisting edema, resisting inflammation, resisting exudation and protecting blood vessels in external formulations. Escin is the most important inflammation-reducing component of horse chestnut fruit and is effective in improving the integrity of the vessel wall by filling up tiny gaps and tiny visible gaps of venules and capillaries.
The Curcuma rhizome extract is dried rhizome extract of Curcuma rhizome of Zingiberaceae, and the main bioactive substances are Curcumin (curcin) and turmerone. The curcumin and the volatile oil have good antibacterial effect on Staphylococcus aureus. The Curcuma rhizome extract has effect in inhibiting various fungi; curcumin has significant inhibitory effect on experimental inflammation of mice and rats, has anti-inflammatory effect on rheumatoid arthritis, and has certain curative effect on spermatic cord edema and tenderness.
The fructus Piperis extract is extract of dried near-ripe or ripe fruit of Piper nigrum L. of Piperaceae, and contains piperine (C)17H19NO3) Jiaweialkali (C)17H19NO3) Piperidine [ (CH)2)5NH and piperitone (C)19H21O3N), and the like. The piperine can promote absorption of medicine, enhance medicine effect, and reduce medicine dosage. Has effects in tranquilizing mind, removing toxic materials, relaxing muscles and tendons, promoting blood circulation, warming middle warmer, expelling cold, stimulating appetite, invigorating qi, eliminating phlegm, regulating viscera, and invigorating kidney-qi.
According to the invention, the glucosamine hydrochloride turmeric extract particles comprise the components of D-glucosamine hydrochloride, turmeric extract, povidone K30, povidone K90. Preferably, the glucosamine hydrochloride turmeric extract particles comprise 77.6 wt% D-glucosamine hydrochloride, 20 wt% turmeric extract, 2 wt% povidone K30, and 0.4 wt% povidone K90, in weight percent.
According to the present invention, the components of the boswellia extract particles comprise boswellia extract, calcium carbonate and hypromellose. Preferably, the components of the frankincense extract particles comprise 52 wt% of frankincense extract, 47 wt% of calcium carbonate and 1 wt% of hypromellose in percentage by weight.
The invention provides a preparation method of an ammonia-sugar composite functional tablet, which comprises the following steps:
s1, mixing D-glucosamine hydrochloride, the turmeric extract and povidone K30 to form a mixture A, mixing povidone K90 with water to prepare 5% serous fluid, mixing the mixture A into the serous fluid, fully dissolving the mixture A until the mixture A is clear and transparent, putting the obtained mixed material into a wet granulator, and uniformly stirring the mixture A and the serous fluid to obtain glucosamine hydrochloride turmeric extract particles;
s2, mixing the frankincense extract, calcium carbonate and hydroxypropyl methylcellulose to obtain a mixture B, preparing 1% slurry by using a proper amount of water and the hydroxypropyl methylcellulose, mixing the mixture B into the slurry, fully dissolving the mixture B until the mixture B is clear and transparent, putting the obtained mixed material into a wet granulator, uniformly stirring, and granulating by a wet method to obtain frankincense extract particles;
s3, mixing the glucosamine hydrochloride curcuma extract particles and the frankincense extract particles with sodium chondroitin sulfate, horse chestnut extract, black pepper extract, vitamin C, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, crospovidone and magnesium stearate, and pressing into tablets;
s4, preparing a coating premix into a solution with the concentration of 20%, and coating the compressed tablets obtained in the step S3 to obtain the tablets.
Preferably, in the step S1, the D-glucosamine hydrochloride of 77.6 wt%, the turmeric extract of 20 wt% and the povidone K30 of 2 wt% are mixed, and the povidone K90 of 0.4 wt% is mixed with water to prepare a serum with a concentration of 5%; in the step S2, the frankincense extract 52 wt%, calcium carbonate 47 wt%, and hypromellose 1 wt% are mixed, and a slurry with a concentration of 1% is prepared by mixing appropriate amount of water with hypromellose.
The invention combines the efficacy of Chinese and western medicine components to carry out compatibility of each component medicine, and selects and optimizes the proportion of each component to complete the preparation of the product. The health care product prepared by the invention enhances the functions of the product in the aspects of inflammation diminishing and bacteria resisting.
The technical scheme of the invention is further explained by combining specific examples.
Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.
Example 1
The preparation of the glucosamine complex functional ingredient dosage form comprises the following steps:
1) preparing particles of a turmeric extract glucosamine hydrochloride; mixing with 77.6 wt% D-glucosamine hydrochloride, 20 wt% Curcuma rhizome extract, and 2 wt% polyvidone K30 to obtain mixture A. Preparing 5 wt% slurry with 0.4 wt% polyvidone K90 with appropriate amount of water, dissolving mixture A into the slurry completely until clear and transparent, adding the obtained mixture into wet granulator, stirring for 10 min, and mixing to obtain granule of glucosamine hydrochloride and Curcuma rhizome extract.
2) And (3) wet granulation of the frankincense extract: mixing 52 parts by weight of frankincense extract, 47 parts by weight of calcium carbonate and 1 part by weight of hydroxypropyl methylcellulose to obtain a mixture B. Preparing hydroxypropyl methylcellulose into slurry with the concentration of 1 wt% by using a proper amount of water, fully dissolving the mixture B into the slurry until the slurry is clear and transparent, putting the obtained mixed material into a wet granulator, stirring for 5 minutes, and uniformly mixing to obtain the frankincense extract particles.
3) Adopting the glucosamine hydrochloride turmeric extract particles prepared in the step 1) and the frankincense extract prepared in the step 2) to perform wet granulation, mixing according to the following component formula, and pressing into tablets:
the turmeric extract particles of glucosamine hydrochloride 975g (65 wt%), sodium chondroitin sulfate 75g (5 wt%), boswellia extract particles 75g (5 wt%), horse chestnut extract 97.5g (6.5 wt%), black pepper extract 7.5g (0.5 wt%), vitamin C15g (1 wt%), microcrystalline cellulose 126g (8.4 wt%), croscarmellose sodium 7.5g (0.5 wt%), silicon dioxide 33g (2.2 wt%), crospovidone 18g (1.2 wt%), magnesium stearate 3g (0.2 wt%).
4) Taking 67.5g (4.5 wt%) of the coating premix, preparing a coating premix solution with the concentration of 20 wt%, and coating the tablets prepared in the step 3).
Example 2
1) Preparation of glucosamine hydrochloride turmeric extract granules: mixing with 77.6 wt% D-glucosamine hydrochloride, 20 wt% Curcuma rhizome extract, and 2 wt% polyvidone K30 to obtain mixture A. Preparing 5 wt% slurry with 0.4 wt% polyvidone K90 with appropriate amount of water, dissolving mixture A into the slurry completely until clear and transparent, adding the obtained mixture into wet granulator, stirring for 10 min, and mixing to obtain granule of glucosamine hydrochloride and Curcuma rhizome extract.
2) And (3) wet granulation of the frankincense extract: mixing 52 parts by weight of frankincense extract, 47 parts by weight of calcium carbonate and 1 part by weight of hydroxypropyl methylcellulose to obtain a mixture B. Preparing hydroxypropyl methylcellulose into slurry with the concentration of 1 wt% by using a proper amount of water, fully dissolving the mixture B into the slurry until the slurry is clear and transparent, putting the obtained mixed material into a wet granulator, stirring for 5 minutes, and uniformly mixing to obtain the frankincense extract particles.
3) Adopting the glucosamine hydrochloride turmeric extract particles prepared in the step 1) and the frankincense extract prepared in the step 2) to perform wet granulation, mixing according to the following component formula, and pressing into tablets:
450g (30 wt%) of turmeric extract granules, glucosamine hydrochloride, 150g (10 wt%) of sodium chondroitin sulfate, 300g (20 wt%) of boswellia extract granules, 225g (15 wt%) of horse chestnut extract, 3g (0.2 wt%) of black pepper extract, 75g (5 wt%) of vitamin C, 178.5g (11.9 wt%) of microcrystalline cellulose, 12g (0.8 wt%) of croscarmellose sodium, 18g (1.2 wt%) of silicon dioxide, 15g (1 wt%) of crospovidone, and 9g (0.6 wt%) of magnesium stearate.
4) Taking 64.5g (4.3 wt%) of the coating premix, preparing a coating premix solution with the concentration of 20 wt%, and coating the tablets prepared in the step 3).
The tablets in example 1 (1.6 g/tablet, 2 tablets per day) and the tablets in example 2 (3 times per day, 2 tablets per time, 0.85 g/tablet) were converted to zebrafish concentrations according to clinical dosage as needed, which were 533 and 850ug/ml, respectively.
Making of models
Treating 3dpf transgenic neutrophilic granulocyte fluorescent zebra fish for 1 hour by using a test article and a positive medicament in advance, and then continuously treating for 2 hours by using copper sulfate in a water-soluble mode to establish a zebra fish inflammation model.
Experimental methods
Randomly selecting 3-day (3dpf) transgenic neutrophilic granulocyte fluorescent zebra fish after fertilization into a six-well plate, randomly selecting 30 fish in each well, wherein the volume of each well is 3ml, using fish culture water to dissolve the transgenic neutrophilic granulocyte fluorescent zebra fish in water in advance, treating the tablets in example 1 and the tablets in example 2 and indomethacin for 1 hour, the concentration of the tablets in example 1 is 533ug/ml, the concentration of the tablets in example 2 is 850ug/ml, and the concentration of the indomethacin is 29ug/ml, setting a normal control group (namely the water-treated zebra fish for fish culture) and a model control group, placing the normal control group and the model control group in an incubator at 28 ℃ for culture for 1 hour, and then using copper sulfate to establish a transgenic neutrophilic granulocyte fluorescent zebra fish inflammation model. After the sample is continuously treated for 2 hours, randomly taking 10 zebra fish from each group, observing under a fluorescence microscope, taking a picture and storing the picture; carrying out image analysis by using Nikon advanced image processing software, calculating the number (N) of neutrophils at the inflammatory part of the zebra fish, expressing a statistical processing result by X +/-SE, and respectively evaluating the anti-inflammatory effect of the test sample on the zebra fish with the inflammation induced by the copper sulfate according to the statistical analysis result of the number of the zebra fish inflammatory neutrophils.
Statistical analysis using analysis of variance and Dunnett's T-test showed significant differences with p < 0.05.
Results of the experiment
The comparison of the number (19) of neutrophils at the verification part of the zebra fish in the model control group with that in the normal control group (3) shows that the zebra fish inflammation model induced by the copper sulfate is successful, and the p is less than 0.001. Compared with a model control group (19), the number of neutrophils (11) at the inflammatory part of the indometacin zebrafish at 29 mu g/mL is less than 0.001, the inflammation regression effect is 42.1%, and the indometacin has obvious anti-inflammatory effect on the inflammatory zebrafish.
When the concentration of the tablet in example 1 is 533. mu.g/mL, the inflammation regression effect of the zebrafish in the case of the number of neutrophils (5) at the inflammation site is 73.7% compared with the model control group (19), wherein p is less than 0.001. When the concentration of the tablet in example 2 is 850 mug/mL, the inflammation regression effect of the zebrafish at the inflammation part is 73.7 percent when the number of the neutrophils (5) is compared with that of a model control group (19) and is less than 0.001. The tablets in example 1 and example 2 had an anti-inflammatory effect on zebrafish, and the inflammation regression rate was the same for both clinically equivalent highest doses.
FIG. 1 is a graph of the effect of each experimental protocol on zebrafish inflammation (neutrophil count) compared to a model control: p is less than 0.001.
Therefore, under the condition of the concentration in the experiment, the tablets prepared in the example 1 and the example 2 of the invention have the effects of promoting cartilage regeneration and resisting inflammation, so that the tablets have the anti-inflammatory effect on rheumatoid arthritis and have certain curative effects on relieving spermatic cord edema and tenderness.
The foregoing is only a preferred application of the present invention, and it should be noted that, for those skilled in the art, various modifications and improvements can be made without departing from the technical principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.
Claims (2)
1. A preparation method of an ammonia-sugar composite functional tablet is characterized by comprising the following steps:
s1, mixing D-glucosamine hydrochloride, the turmeric extract and povidone K30 to form a mixture A, mixing povidone K90 with water to prepare 5% serous fluid, mixing the mixture A into the serous fluid, fully dissolving the mixture A until the mixture A is clear and transparent, putting the obtained mixed material into a wet granulator, and uniformly stirring the mixture A and the serous fluid to obtain glucosamine hydrochloride turmeric extract particles;
s2, mixing the frankincense extract, calcium carbonate and hydroxypropyl methylcellulose to obtain a mixture B, preparing 1% slurry by using a proper amount of water and the hydroxypropyl methylcellulose, mixing the mixture B into the slurry, fully dissolving the mixture B until the mixture B is clear and transparent, putting the obtained mixed material into a wet granulator, uniformly stirring, and granulating by a wet method to obtain frankincense extract particles;
s3, mixing the glucosamine hydrochloride curcuma extract particles and the frankincense extract particles with sodium chondroitin sulfate, horse chestnut extract, black pepper extract, vitamin C, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, crospovidone and magnesium stearate, and pressing into tablets;
s4, preparing a coating premix into a solution with the concentration of 20%, and coating the compressed tablets obtained in the step S3 to obtain the tablets.
2. The preparation method according to claim 1, wherein the step S1 is performed by mixing 77.6 wt% of D-glucosamine hydrochloride, 20 wt% of turmeric extract and 2 wt% of povidone K30, and mixing 0.4 wt% of povidone K90 with water to prepare 5% slurry; in the step S2, the frankincense extract 52 wt%, calcium carbonate 47 wt%, and hypromellose 1 wt% are mixed, and a slurry with a concentration of 1% is prepared by mixing appropriate amount of water with hypromellose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210151242.5A CN114343184A (en) | 2020-12-29 | 2020-12-29 | Preparation method of ammonia sugar composite functional tablet |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011599893.8A CN112715944A (en) | 2020-12-29 | 2020-12-29 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
| CN202210151242.5A CN114343184A (en) | 2020-12-29 | 2020-12-29 | Preparation method of ammonia sugar composite functional tablet |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011599893.8A Division CN112715944A (en) | 2020-12-29 | 2020-12-29 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114343184A true CN114343184A (en) | 2022-04-15 |
Family
ID=75611525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011599893.8A Pending CN112715944A (en) | 2020-12-29 | 2020-12-29 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
| CN202210151242.5A Pending CN114343184A (en) | 2020-12-29 | 2020-12-29 | Preparation method of ammonia sugar composite functional tablet |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011599893.8A Pending CN112715944A (en) | 2020-12-29 | 2020-12-29 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112715944A (en) |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6224871B1 (en) * | 1998-03-11 | 2001-05-01 | Reliv International, Inc. | Dietary supplement for nutritionally promoting healthy joint function |
| CA2599963A1 (en) * | 2005-03-04 | 2006-09-14 | Abbott Laboratories | Nutritional products for ameliorating symptoms of rheumatoid arthritis |
| CN101239168A (en) * | 2008-01-11 | 2008-08-13 | 王玉亮 | Composition with ease pain anti-inflammatory action |
| CN102600098A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Glucosamine sustained release preparation and preparation method thereof |
| CN102599508A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Preparation for preparing chondroitin glucosamine particles by wet method and preparation method |
| CN104324066A (en) * | 2014-02-17 | 2015-02-04 | 广东省中医药工程技术研究院 | Preparation method of frankincense particles |
| CN104664402A (en) * | 2015-03-26 | 2015-06-03 | 江苏康缘药业股份有限公司 | Composition for increasing bone density and preparation method and application of composition |
| US20170112823A1 (en) * | 2015-10-27 | 2017-04-27 | Health Naturally, LLC | Compositions and methods to treat neuropathy and related conditions |
| CN107668724A (en) * | 2017-11-20 | 2018-02-09 | 江苏艾兰得营养品有限公司 | A kind of compound preparation of ammonia sugar chondroitin collagen turmeric and preparation method thereof |
| US20190134140A1 (en) * | 2017-11-03 | 2019-05-09 | Lauranell Harrison BURCH | Orally administered composition for treating cystic fibrosis, copd, asthma and other inflammatory conditions |
| US20190224267A1 (en) * | 2016-08-19 | 2019-07-25 | Aurea Biolabs Private Limited | An anti-inflammatory composition for the treatment of acute joint inflammation and a process for preparation thereof |
| CN110507620A (en) * | 2019-09-09 | 2019-11-29 | 山东润德生物科技有限公司 | A kind of compound glucosamine sulfate dispersible tablet and preparation method thereof |
| CN110680808A (en) * | 2019-11-08 | 2020-01-14 | 山东润德生物科技有限公司 | Amino sugar chewable tablet and preparation method thereof |
| CN110872361A (en) * | 2019-12-06 | 2020-03-10 | 中国科学院烟台海岸带研究所 | Glucosamine chondroitin sulfate, preparation method and application |
| CN111000817A (en) * | 2019-12-31 | 2020-04-14 | 众生健康(广东)科技有限公司 | Glucosamine chondroitin calcium tablet and preparation method thereof |
| CN111297932A (en) * | 2019-12-30 | 2020-06-19 | 江苏雅博动物健康科技有限责任公司 | Joint maintenance composite tablet for pets and preparation method thereof |
| CN111388648A (en) * | 2020-04-09 | 2020-07-10 | 汪冰 | Composition for relieving joint swelling, pain and joint stiffness and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778325A (en) * | 2004-11-17 | 2006-05-31 | 大道隆达（北京）医药科技发展有限公司 | Disperse tablet for activating bood and stopping pain and its preparation |
| CN111617136A (en) * | 2013-10-28 | 2020-09-04 | Atp研究有限公司 | Pain relief formulations and methods of treatment |
-
2020
- 2020-12-29 CN CN202011599893.8A patent/CN112715944A/en active Pending
- 2020-12-29 CN CN202210151242.5A patent/CN114343184A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6224871B1 (en) * | 1998-03-11 | 2001-05-01 | Reliv International, Inc. | Dietary supplement for nutritionally promoting healthy joint function |
| CA2599963A1 (en) * | 2005-03-04 | 2006-09-14 | Abbott Laboratories | Nutritional products for ameliorating symptoms of rheumatoid arthritis |
| CN101239168A (en) * | 2008-01-11 | 2008-08-13 | 王玉亮 | Composition with ease pain anti-inflammatory action |
| CN102600098A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Glucosamine sustained release preparation and preparation method thereof |
| CN102599508A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Preparation for preparing chondroitin glucosamine particles by wet method and preparation method |
| CN104324066A (en) * | 2014-02-17 | 2015-02-04 | 广东省中医药工程技术研究院 | Preparation method of frankincense particles |
| CN104664402A (en) * | 2015-03-26 | 2015-06-03 | 江苏康缘药业股份有限公司 | Composition for increasing bone density and preparation method and application of composition |
| US20170112823A1 (en) * | 2015-10-27 | 2017-04-27 | Health Naturally, LLC | Compositions and methods to treat neuropathy and related conditions |
| US20190224267A1 (en) * | 2016-08-19 | 2019-07-25 | Aurea Biolabs Private Limited | An anti-inflammatory composition for the treatment of acute joint inflammation and a process for preparation thereof |
| US20190134140A1 (en) * | 2017-11-03 | 2019-05-09 | Lauranell Harrison BURCH | Orally administered composition for treating cystic fibrosis, copd, asthma and other inflammatory conditions |
| CN107668724A (en) * | 2017-11-20 | 2018-02-09 | 江苏艾兰得营养品有限公司 | A kind of compound preparation of ammonia sugar chondroitin collagen turmeric and preparation method thereof |
| CN110507620A (en) * | 2019-09-09 | 2019-11-29 | 山东润德生物科技有限公司 | A kind of compound glucosamine sulfate dispersible tablet and preparation method thereof |
| CN110680808A (en) * | 2019-11-08 | 2020-01-14 | 山东润德生物科技有限公司 | Amino sugar chewable tablet and preparation method thereof |
| CN110872361A (en) * | 2019-12-06 | 2020-03-10 | 中国科学院烟台海岸带研究所 | Glucosamine chondroitin sulfate, preparation method and application |
| CN111297932A (en) * | 2019-12-30 | 2020-06-19 | 江苏雅博动物健康科技有限责任公司 | Joint maintenance composite tablet for pets and preparation method thereof |
| CN111000817A (en) * | 2019-12-31 | 2020-04-14 | 众生健康(广东)科技有限公司 | Glucosamine chondroitin calcium tablet and preparation method thereof |
| CN111388648A (en) * | 2020-04-09 | 2020-07-10 | 汪冰 | Composition for relieving joint swelling, pain and joint stiffness and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112715944A (en) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6224871B1 (en) | Dietary supplement for nutritionally promoting healthy joint function | |
| CN102224896B (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| CN104645332A (en) | Pharmaceutical composition for relieving and preventing arthritis | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN1947724A (en) | Compound amino-glucose hydrochloride, chondroitin sulfate effervescent, tablets prepn. method and use thereof | |
| CN116726141B (en) | Composition for preventing and relieving osteoarthropathy and application thereof | |
| CN114343184A (en) | Preparation method of ammonia sugar composite functional tablet | |
| ZA200107547B (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration. | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| RU2381029C1 (en) | Combined chondroprotective pharmaceutical composition | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| KR20050101143A (en) | Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin | |
| RU2182011C1 (en) | Biologically active food additive to prevent reduction of immune system | |
| KR101423316B1 (en) | Composition for prevention or treatment of osteoarthritis including extracts of Phyllanthus tenellus | |
| CN112870207A (en) | Composition for preventing and/or treating organ fibrosis and application and preparation thereof | |
| CN101450088A (en) | Medicine composition with anti-oxidation and senescence prevention function and preparation method thereof | |
| CN112870250B (en) | Composition for preventing and treating organ fibrosis and application and preparation thereof | |
| CN103610686A (en) | New composition capable of protecting liver, detoxifying and relieving pain and preparation method | |
| RU2813891C1 (en) | Pharmaceutical agent for treating arthrological diseases | |
| AU5778801A (en) | Improvements in effervescent tablet manufacture | |
| WO2010109736A1 (en) | Cartilage production promoter and prophylactic or therapeutic agent for diseases associated with cartilage damage | |
| CN107737191A (en) | The saline cistanche composition and preparation technology of a kind of kidney-tonifying health-care | |
| CN112807318B (en) | Application of 1,2,3,4, 6-O-pentagalloyl glucose in preparation of drugs for preventing and/or treating pulmonary fibrosis | |
| CN1092519C (en) | Chinese medicine for argiitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220415 |